---
title: "AUPH.US (AUPH.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AUPH.US/news.md"
symbol: "AUPH.US"
name: "AUPH.US"
parent: "https://longbridge.com/en/quote/AUPH.US.md"
datetime: "2026-03-04T09:20:00.634Z"
locales:
  - [en](https://longbridge.com/en/quote/AUPH.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AUPH.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AUPH.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/AUPH.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/AUPH.US/news.md)


# AUPH.US (AUPH.US) — Related News

### [Aurobindo Pharma Says Eugia Pharma Launches Pomalidomide Capsules In US](https://longbridge.com/en/news/277741900.md)
*2026-03-04T07:39:11.000Z*
> March 4 (Reuters) - Aurobindo Pharma LtdS) :* EUGIA PHARMA LAUNCHES POMALIDOMIDE CAPSULES IN US Source text: Further com

### [UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors | URGN Stock News](https://longbridge.com/en/news/277467774.md)
*2026-03-02T04:55:00.000Z*
> UroGen Pharma Ltd. has announced a refinancing agreement with Pharmakon Advisors, reducing its cost of capital to 8.25% 

### [Aurinia’s LUPKYNIS Strength And Aritinercept Progress Versus Valuation Signals](https://longbridge.com/en/news/277382884.md)
*2026-03-02T01:02:13.000Z*
> Aurinia Pharmaceuticals reported strong sales of LUPKYNIS, boosting net income due to a tax benefit. The company has ini

### [Aurobindo Pharma says completion of US FDA inspection at unit I of Eugia Pharma Specialities](https://longbridge.com/en/news/277185755.md)
*2026-02-27T11:00:56.000Z*
> Aurobindo Pharma says completion of US FDA inspection at unit I of Eugia Pharma Specialities

### [Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets](https://longbridge.com/en/news/277095761.md)
*2026-02-26T21:06:23.000Z*
> Aurinia Pharmaceuticals (AUPH) shares fell 3.15% to $13.98 after reporting strong fourth-quarter earnings of 26 cents pe

### [Earnings Summary: Aurinia Pharmaceuticals Q4](https://longbridge.com/en/news/277027416.md)
*2026-02-26T11:02:29.000Z*
> Aurinia Pharmaceuticals (NASDAQ:AUPH) reported Q4 earnings on February 26, 2026, beating estimates by 628.57% with an EP

### [Aurobindo Pharma says Eugia Pharma receives USFDA approval for everolimus tablets](https://longbridge.com/en/news/277037923.md)
*2026-02-26T12:10:52.000Z*
> Aurobindo Pharma says Eugia Pharma receives USFDA approval for everolimus tablets

### [Canada's Aurinia Pharma Q4 revenue jumps on LUPKYNIS demand](https://longbridge.com/en/news/277028862.md)
*2026-02-26T11:15:15.000Z*
> Aurinia Pharmaceuticals reported a 29% year-over-year revenue growth in Q4, driven by strong demand for LUPKYNIS. The co